Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Items 601–700 of 860

The trend of managing prostate cancer in Taiwan
Wong, W.-Y., Chen, S.-C., Chueh, S., & Chen, J. (2004) · International Journal of Urology · doi:10.1111/j.1442-2042.2004.00836.x · Cited by 5
Management and Characteristics of Patients with Metastatic Prostate Cancer in a Cohort of New Zealand Men
Lawrenson, R. A., Lao, C., Obertová, Z., Brown, C., Holmes, M., Tyrie, L., Scott, N., Fong, P. C. C., & Laking, G. R. (2014) · Oncology · doi:10.1159/000368319 · Cited by 5
Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer
Gafanov, R. A. (2016) · Cancer Urology · doi:10.17650/1726-9776-2016-12-1-63-68 · Cited by 5
Environmental inhibitors of the expression of cytochrome P450 17A1 in mammals
Peng, Z., Xueb, G., Chen, W., & Xia, S. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2019.02.007 · Cited by 5
Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer
Alva, A. S., & Hussain, M. (2013) · Drugs · doi:10.1007/s40265-013-0106-3 · Cited by 5
Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo Outcome
Njoroge, R. N., Vatapalli, R. J., & Abdulkadir, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00077 · Cited by 5
Secondary Hormonal Manipulation
Merseburger, A. S., Belka, C., Behmenburg, K., & Stenzl, A. (2008) · KARGER eBooks · doi:10.1159/000139883 · Cited by 5
Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales
Berlín, A., & Fernández, M. I. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015000200010 · Cited by 5
Intra-prostatic androgen levels during various androgen-blockade regimens
Nishiyama, T. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.002 · Cited by 5
Routine interval computed tomography to detect new soft‐tissue disease might be unnecessary in patients with androgen‐independent prostate cancer and metastasis only to bone
Wu, S., Jones, E. C., Gulley, J. L., Arlen, P. M., Chen, C. C., Figg, W. D., & Dahut, W. L. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06654.x · Cited by 5
Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second‐Line Hormonal Therapy (CALGB 9181)
Halabi, S., Conaway, M. R., Small, E. J., Vogelzang, N. J., & Dawson, N. A. (2001) · The Prostate Journal · doi:10.1046/j.1525-1411.2001.31003.x · Cited by 5
Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
Zampino, M. G., Verri, E., Locatelli, M., Curigliano, G., Ascione, G., Sbanotto, A., Rocca, A., Verweij, F., Matei, V. D., Scardino, E., et al. (2006) · PubMed · Cited by 5
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center
Koff, S. G., Connelly, R. R., Bauer, J. J., McLeod, D. G. R., & Moul, J. W. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500551 · Cited by 5
Self-citation
Adult Genitourinary Cancer—Prostate and Bladder
Malkowicz, S. B., Vaughn, D. J., & Wein, A. J. (2007) · Elsevier eBooks · doi:10.1016/b978-141603848-1.10015-4 · Cited by 5
Overview of Current Treatment Strategies in Prostate Cancer
Bono, A. V. (2004) · European Urology Supplements · doi:10.1016/j.eursup.2003.12.002 · Cited by 5
Hormonal Therapy for Advanced Prostate Cancer
Vaughn, D. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00011 · Cited by 5
Observed Advantages of the STAMPEDE Study Design
Scher, H. I. (2014) · European Urology · doi:10.1016/j.eururo.2014.12.004 · Cited by 5
Management of prostate cancer. Part 3: metastatic disease
Shah, J., Khaksar, S., & Sooriakumaran, P. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.813 · Cited by 5
The male climacterium: Clinical signs and symptoms of a changing endocrine environment
van den Beld, A. W., & Lamberts, S. W. J. (2000) · The Prostate · doi:10.1002/1097-0045(2000)45:10+ · Cited by 21
Management of castration‐resistant prostate cancer: a call to urologists
Fitzpatrick, J. M. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11332.x · Cited by 4
High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
Hsieh, Y., Chiang, B., Wu, C., Liao, C., Lin, C.-D., & Chen, C. (2021) · Cancers · doi:10.3390/cancers13163966 · Cited by 4
Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
Jin, D., Jin, K., Chen, B., Zhou, X., Yuan, Q., Zhang, Z., Wei, Q., & Qiu, S. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002021 · Cited by 4
Prise en charge des cancers de la prostate métastatiques hormonosensibles (CPMHS)
Gravis, G., Salem, N., & Walz, J. C. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2014.12.003 · Cited by 4
Advances in Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer
Pant, M. K., Abughaban, A., & Aragon‐Ching, J. B. (2014) · Future Oncology · doi:10.2217/fon.14.128 · Cited by 4
Hormonal therapy and chemotherapy for advanced prostate cancer
Lee, J. (2015) · Journal of Korean Medical Association · doi:10.5124/jkma.2015.58.1.30 · Cited by 4
Blood cells and their use in active immunotherapy of prostate cancer
Zhang, S. Y., Thara, E., Quinn, D. I., & Dorff, T. B. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19188 · Cited by 4
Pharmacogenetics- and Pharmacogenomics-Based Rational Clinical Trial Designs in Oncology
Qin, R., & Kohli, M. (2013) · Personalized Medicine · doi:10.2217/pme.13.78 · Cited by 4
Androgen receptor roles in benign and malignant prostate disease
Wang, J., Shang, Z., & Niu, Y. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0564-x · Cited by 4
Predictors of overall survival in patients with metastatic castration-resistant prostate cancer
Маркова, А. С., Борисовна, П. С., Камолов, Б. Ш., Gridneva, Y. V., Kalinin, S. A., Peters, M. V., & Matveev, V. B. (2015) · Cancer Urology · doi:10.17650/1726-9776-2015-11-2-77-84 · Cited by 4
Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
Bağcıoğlu, M., Surcel, C. I., Özcan, S., Mirvald, C., Karagöz, M. A., Karadağ, M. A., Hurі, E., & Sarıca, K. (2017) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2017.4.282 · Cited by 4
Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy
Park, H. S., Shin, H. B., Woo, S. H., Jeon, S. H., Lee, S. H., Kang, S. H., Shim, J. S., Shin, D. W., & Park, J. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02847-y · Cited by 4
Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer
Mohler, J. L., & Titus, M. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_23 · Cited by 4
Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy
Chen, C., Hsieh, J., Huang, K., Pu, Y., & Chang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105091 · Cited by 4
Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer
Batty, N., Yarlagadda, N., & Пили, Р. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0112 · Cited by 4
The necessity and the value of placebo
Singer, E. A. (2004) · Science and Engineering Ethics · doi:10.1007/s11948-004-0062-0 · Cited by 4
Antiandrogen therapy in prostate cancer
Szmulewitz, R. Z., & Posadas, E. M. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.10.003 · Cited by 4
Use of combined androgen blockade for advanced prostate cancer in British Columbia
Chau, A., de Lemos, M. L., Pickles, T., Blood, P. A., Kovacic, L., Abadi, S., & Barnett, J. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209337661 · Cited by 4
Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer
Kaliks, R. A., Santi, P. X., Cardoso, A. P. G., & del Giglio, A. (2010) · International braz j urol · doi:10.1590/s1677-55382010000300006 · Cited by 4
Prostate cancer management—helping your patient choose what is best for him
Heyns, C. F., & der Merwe, A. V. (2008) · South African Family Practice · doi:10.1080/20786204.2008.10873756 · Cited by 4
Non-steroidal anti-androgens in prostate cancer - current treatment practice
Han, M., & Nelson, J. B. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.3.443 · Cited by 4
The Southwest Oncology Group: Progress in Cancer Research
Coltman, C. A. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.07.001 · Cited by 4
The Anti‐Androgen Transfer
Kim, S. P., Moran, E. M., Bowes, E., Tennant, A. G., & Bennett, C. L. (2000) · The Prostate Journal · doi:10.1046/j.1525-1411.2000.22006.x · Cited by 4
An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer
Jordan, V. C., & Furr, B. J. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59259-152-7_1 · Cited by 4
[Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade].
Tałałaj, M., Kapitan-Malinowska, B., Dębski, K., Nowakowski, R., Marcinowska-Suchowierska, E., & Witeska, A. (2005) · PubMed · Cited by 4
Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials
Rashid, M., Ramesh, M., Shamshavali, K., Dang, A., Patel, H. J., & Undela, K. (2019) · Reviews on Recent Clinical Trials · doi:10.2174/1574887114666191105152404 · Cited by 4
Chemotherapy for localized, high-risk prostate cancer
Narayan, S., Smith, D. C., & Sandler, H. M. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)70008-3 · Cited by 4
The Need for Improved Therapeutic Strategies for Patients with Metastatic Hormone-Refractory Prostate Cancer
Anderson, J. (2006) · European Urology Supplements · doi:10.1016/j.eursup.2006.06.016 · Cited by 4
Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
MacVicar, G. R., & Hussain, M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0103-7 · Cited by 4
Immediate Treatment after PSA Progression
Seitz, C., Mesut Remzi, A., & Djavan, B. (2005) · European Urology Supplements · doi:10.1016/j.eursup.2005.01.012 · Cited by 4
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
Suzman, D. L., & Antonarakis, E. S. (2014) · PubMed · Cited by 3
NEW TREATMENT STRATEGIES IN ADVANCED PROSTATE CANCER
Small, E. J., & Reese, D. (2000) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(05)70156-1 · Cited by 3
Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade
Vojinov, S., Levakov, I., Jeremić, D., Zivojinov, S., & Marusic, G. (2011) · Vojnosanitetski pregled · doi:10.2298/vsp1104321v · Cited by 3
Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer
Kyriakopoulos, C. E., & Liu, G. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000215 · Cited by 3
Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients
Özülker, T., & Özülker, F. (2020) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2020.01.004 · Cited by 3
Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis
Xiao, S., Yin, H., Lv, X., Wang, Z., Jiang, L., Xia, Y., & Liu, Y. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16176 · Cited by 3
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer
Fukuokaya, W., Mori, K., Yanagisawa, T., Urabe, F., Rajwa, P., Briganti, A., Shariat, S. F., Matsubara, N., Kimura, T., & Hirakawa, A. (2025) · Cancer · doi:10.1002/cncr.35819 · Cited by 3
Cell Biology of Prostate Cancer and Molecular Targets
Gleave, M. E., Cox, M., & Wang, Y. Z. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_1 · Cited by 3
Truncated Androgen Receptor Splice Variants in Prostate Cancer
Lonergan, P. E., & Tindall, D. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_13 · Cited by 3
Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer
Nasser, N. J. (2022) · Cancers · doi:10.3390/cancers14081959 · Cited by 3
Bloqueo androgénico en cáncer de próstata, revisión de la literatura
Carlos, A.-K. J., Elena, S.-V., María, M.-P., Manuel, C., & Alejandro, J. (2012) · Revista Mexicana de Urología · Cited by 3
Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer
Thompson, I. M., Basler, J. W., Leach, R. J., Troyer, D. A., Klein, E. A., & Brawley, O. W. (2003) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(02)00302-2 · Cited by 3
Self-citation
Prostate-Specific Antigen Dynamics Predict Risk of Progression in Advanced Prostate Cancer Treated with Bicalutamide plus Castration
Altwein, J. E., & Schmidt, A. (2002) · Urologia Internationalis · doi:10.1159/000058439 · Cited by 3
Current Medical and Surgical Options for Androgen Deprivation in Prostate Cancer Patients
Bayraktar, S., & Abdel–Wahab, M. (2010) · The Open Prostate Cancer Journal · doi:10.2174/1876822901003010039 · Cited by 3
Anemia Related to Hormonal Ablation Therapy for Prostate Cancer
Oh, W. K. (2001) · The Prostate Journal · doi:10.1046/j.1525-1411.2001.003001014.x · Cited by 3
Dealing with non-cancerous findings on prostate biopsy
Brand, T. C., Thibault, G. P., & Basler, J. W. (2006) · Current Urology Reports · doi:10.1007/s11934-006-0020-2 · Cited by 3
Androgen Receptor Antagonists
Shen, H. C., Taplin, M., & Balk, S. P. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_6 · Cited by 3
To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
Caffo, O., Maines, F., Kinspergher, S., Veccia, A., & Messina, C. G. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1856661 · Cited by 3
Prostate Cancer
Nelson, W. G., Carter, H. B., DeWeese, T. L., & Eisenberger, M. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50092-0 · Cited by 3
Self-citation
Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?
Canby‐Hagino, E., Swanson, G. P., Crawford, E. D., Basler, J. W., Hernández, J., & Thompson, I. M. (2005) · Current Prostate Reports · doi:10.1007/s11918-005-0009-1 · Cited by 3
Self-citation
Prostatakarzinom: palliative Therapie
Huber, J. C., Brogsitter, C., Kotzerke, J., Hölscher, T., Baumann, M. A., Fröhner, M., & Wirth, M. P. (2015) · Springer eBooks · doi:10.1007/978-3-642-41168-7_144-1 · Cited by 3
The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer
Eisenberger, M. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-079-3_16 · Cited by 3
Self-citation
Advanced Prostate Cancer
Naughton, M., & Picus, J. (2002) · American Journal of Cancer · doi:10.2165/00024669-200201010-00003 · Cited by 3
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): Positioning statement from the Spanish Association of Urology
Villavicencio, H., Hernández, C., Gómez, A., Cozar, J. M., Rodríguez-Antolín, A., Prieto, L., de Cabo, M., Malet, J., Extramiana, J., Mata, J., et al. (2013) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2013.04.001 · Cited by 3
Tratamiento del cáncer de próstata y cáncer renal con fármacos orales (abiraterona y antiangiogénicos): posicionamiento de la Asociación Española de Urología
Villavicencio, H., Hernández, C., Gómez, A., Cozar, J. M., Rodríguez-Antolín, A., Prieto, L., de Cabo, M., Malet, J., Extramiana, J., Mata, J., et al. (2013) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2013.04.001 · Cited by 3
Luteinizing hormone–releasing hormone monotherapy: a viable option for treatment of prostate cancer?
Schellhammer, P. F. (2001) · Urology · doi:10.1016/s0090-4295(01)01236-5 · Cited by 3
The role of the urologist in adjuvant chemotherapy trials for prostate cancer
Presti, J. C. (1999) · Urology · doi:10.1016/s0090-4295(99)00454-9 · Cited by 3
Prostate Cancer Management Under Scrutiny: One Man's Meta-Analysis Is Another Man's Poisson
Raghavan, D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3371 · Cited by 3
Hormonal Treatment of Prostate Cancer
Garnick, M. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401015 · Cited by 3
Detection of Residual Disease in Childhood Acute Lymphoblastic Leukemia
Faderl, S. H., & Estrov, Z. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400218 · Cited by 3
Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410–8
Gregucci, F., & Fiorentino, A. (2018) · European Urology · doi:10.1016/j.eururo.2018.12.025 · Cited by 3
HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complexPreprint
Lingadahalli, S., Ersoy-Fazlioglu, B., Altıntaş, U. B., Cingöz, A., Tekoglu, E., Yu, I. P. L., Dikbas, U. M., Andomat, H., Kulaç, İ., Morova, T., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.04.556101 · Cited by 3
Androgen Ablation Therapy and Prostate Cancer: An Update
Omabe, M. (2013) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2013/2637 · Cited by 2
Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer
Dorff, T. B., Tangen, C. M., Crawford, E. D., Petrylak, D. P., Higano, C. S., Raghavan, D., Quinn, D. I., Vogelzang, N. J., & Thompson, I. M. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009343454 · Cited by 2
Self-citation
Challenges in treating advanced disease.
Petrylak, D. P. (2013) · PubMed · Cited by 2
Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience
Detti, B., Franceschini, D., Saieva, C., Lucia, D. B., Mohammed, B., Meattini, I., Vanessa, D. C., Pasquetti, E. M., Furfaro, I. F., Anna, M., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.958233 · Cited by 2
Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China
Zhang, Y., Ding, L., Zheng, Y., Wang, K., Xia, W., Wang, J., & Ge, P. (2023) · PeerJ · doi:10.7717/peerj.14500 · Cited by 2
In silico elucidation of novel anticancer lead molecules targeting human prostate specific gene-1 protein
Waziri, F., Vijayan, R., Sahar, T., Anwar, S., Gourinath, S., Jain, S. K., & Wajid, S. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1477623 · Cited by 2
Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients
Pathak, S., Thekkekara, R. J., Yadav, U., Ahmed, A. T., Yim, B. T., Lad, T. E., Mullane, M. R., Batra, K. K., Aronow, W. S., & Psutka, S. P. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001085 · Cited by 2
Zytoreduktive radikale Prostatektomie beim Prostatakarzinom mit minimaler ossärer Metastasierung
Heidenreich, A., Pfister, D. J. K. P., Brehmer, B., & Porres, D. (2014) · Der Urologe · doi:10.1007/s00120-014-3697-8 · Cited by 2
Metastatic Prostate Cancer
Levin, B. M., Vaughn, D. J., & Malkowicz, B. S. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302020-00002 · Cited by 2
Recommendations on the management of prostate cancer - a round table conference
Senkus-Konefka, E., Antoniewicz, A. A., Borkowski, A. G., Borówka, A., Demkow, T., Dobruch, J. T., Fijuth, J., Jassem, J., Krzakowski, M. J., Ligaj, M., et al. (2007) · Via Medica Journals · Cited by 2
Androgen-Deprivation Therapy in Prostate Cancer: Clinical Evidence and Future Perspectives
Pinto, F., Calamo, A., Totaro, A., Sacco, E., Volpe, A., Racioppi, M., D’Addessi, A., & Bassi, P. (2010) · Urologia Journal · doi:10.1177/039156031007700201 · Cited by 2
Drug Therapies for Metastatic Castration-Resistant Prostate Cancer
El-Bahesh, E., Finianos, A. N., Alfaraj, A., & Aragon‐Ching, J. B. (2015) · Future Oncology · doi:10.2217/fon.15.168 · Cited by 2
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy
Du, J. C., Yang, Q., Chen, X.-S., Tian, J., & Yao, X. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2291-x · Cited by 2
Evaluation of core and surface body temperatures, prevalence, onset, duration and severity of hot flashes in men after bilateral orchidectomy for prostate cancer
Aziz, N. A., & Heyns, C. F. (2008) · International braz j urol · doi:10.1590/s1677-55382008000100004 · Cited by 2
Análise de complicações em pacientes portadores de câncer de próstata metastático submetidos à orquiectomia bilateral
Silva, B. M. E., Neto, J. A. B. D. S., & de Lima, R. L. (2010) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/s0100-69912010000400006 · Cited by 2
THERAPY FOR ADVANCED AND HORMONE REFRACTORY CANCER OF THE PROSTATE
Schellhammer, P. F., & Pienta, K. J. (2000) · Cited by 2
New Medical Strategies: The Role of Oncologist in an MDT
Longo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-04385-2_10 · Cited by 2
Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy
Yamamoto, Y., Nozawa, M., Itami, Y., Kobayashi, Y., Saito, Y., Shimizu, N., Minami, T., Hayashi, T., Tsuji, H., Yoshimura, K., et al. (2013) · Journal of Cancer Research & Therapy · doi:10.14312/2052-4994.2013-30 · Cited by 2
Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer under Palliative Androgen Deprivation Treatment
Abu-Hamar, A. E. H., & Gameel, T. (2010) · Journal of Men s Health · doi:10.1016/j.jomh.2010.09.049 · Cited by 2

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks